Last reviewed · How we verify
SYHA1813
At a glance
| Generic name | SYHA1813 |
|---|---|
| Sponsor | Shanghai Runshi Pharmaceutical Technology Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma (PHASE2)
- Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors. (PHASE1, PHASE2)
- Relative Bioavailability and Food Effect of SYHA1813 Oral Solution in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SYHA1813 CI brief — competitive landscape report
- SYHA1813 updates RSS · CI watch RSS
- Shanghai Runshi Pharmaceutical Technology Co., Ltd portfolio CI